Whatever the brain does on drugs, it may be capable of without them.
Shifting from insecure to secure attachments may help rescue patients from pathological mental states.
The relationship between efficacy and potency is a key concept in understanding psychedelic drug pharmacology.
Recent antidepressant exposure may reduce the treatment efficacy of MDMA.
Research suggests that DMT may not be the only compound responsible for ayahuasca's effects.
This compound exhibits reduced cardiotoxicity, psychoplastogen characteristics, and potential therapeutic effects in animal models.
“I believe one person can produce enough 5-MeO-DMT to supply everyone that would ever want it.”
According to IIT, psychedelics cause concepts to form more links with each other than usual. This might explain several phenomena observed in psychedelic mind-states.
New research shows that ketamine reduces self-dislike, loosening the rigid prejudice toward oneself that can constitute depression.
The “psychedelic drug” label appears to define a clear-cut category. However, there are lesser-known research chemicals that depict more diffuse boundaries in this classification.